[go: up one dir, main page]

MX2016012045A - Derivados de estradiol 6-sustituido para el tratamiento de la enfermedad de alzheimer. - Google Patents

Derivados de estradiol 6-sustituido para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2016012045A
MX2016012045A MX2016012045A MX2016012045A MX2016012045A MX 2016012045 A MX2016012045 A MX 2016012045A MX 2016012045 A MX2016012045 A MX 2016012045A MX 2016012045 A MX2016012045 A MX 2016012045A MX 2016012045 A MX2016012045 A MX 2016012045A
Authority
MX
Mexico
Prior art keywords
disease
alzheimer
treatment
substituted estradiol
estradiol derivatives
Prior art date
Application number
MX2016012045A
Other languages
English (en)
Inventor
G Yarger James
H Nye Steven
Original Assignee
Endece Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endece Llc filed Critical Endece Llc
Publication of MX2016012045A publication Critical patent/MX2016012045A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se revela un método para tratar la Enfermedad de Alzheimer con compuestos estradiol 6-sustituido de la fórmula: (ver Fórmula) Los métodos se pueden usar para tratar una variedad de enfermedades relacionadas con la regulación ascendente de la lipoproteína lipasa o la apolipoproteína C2.
MX2016012045A 2014-03-19 2015-03-19 Derivados de estradiol 6-sustituido para el tratamiento de la enfermedad de alzheimer. MX2016012045A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461955578P 2014-03-19 2014-03-19
PCT/US2015/021538 WO2015143201A2 (en) 2014-03-19 2015-03-19 6-substituted estradiol derivatives for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2016012045A true MX2016012045A (es) 2017-01-19

Family

ID=54141046

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012045A MX2016012045A (es) 2014-03-19 2015-03-19 Derivados de estradiol 6-sustituido para el tratamiento de la enfermedad de alzheimer.

Country Status (11)

Country Link
US (1) US20150265630A1 (es)
EP (1) EP3119402A4 (es)
JP (1) JP2017512769A (es)
KR (1) KR20160136363A (es)
CN (1) CN106255501A (es)
AU (2) AU2015231172A1 (es)
BR (1) BR112016021408A2 (es)
CA (1) CA2940536A1 (es)
MX (1) MX2016012045A (es)
SG (1) SG11201607693WA (es)
WO (1) WO2015143201A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019113A2 (pt) * 2019-06-03 2021-12-14 Aihol Corp Conjugados de hialuronano e usos dos mesmos
US20210024568A1 (en) * 2019-07-23 2021-01-28 Endece Llc Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
US20080200441A1 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators associated pharmaceutical compositions and methods of use
KR102080151B1 (ko) * 2011-03-21 2020-02-21 엔디씨, 엘엘씨 신경 축색들의 재수초화에 사용하기 위한 6-치환 에스트라디올 유도체들

Also Published As

Publication number Publication date
EP3119402A2 (en) 2017-01-25
WO2015143201A2 (en) 2015-09-24
CA2940536A1 (en) 2015-09-24
AU2018201003A1 (en) 2018-03-01
SG11201607693WA (en) 2016-10-28
EP3119402A4 (en) 2017-11-01
AU2015231172A1 (en) 2016-09-08
US20150265630A1 (en) 2015-09-24
JP2017512769A (ja) 2017-05-25
CN106255501A (zh) 2016-12-21
BR112016021408A2 (pt) 2017-12-19
KR20160136363A (ko) 2016-11-29

Similar Documents

Publication Publication Date Title
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
ZA201802496B (en) Jak kinase inhibitor compounds for treatment of respiratory disease
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
EP3562514A4 (en) GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
PH12015501920B1 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS
NZ726317A (en) Tank-binding kinase inhibitor compounds
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
IL247085B (en) Methods for treating Alzheimer's disease
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
ZA201605341B (en) Methods of treating alzheimer's disease
EA201791993A1 (ru) Способы лечения протеинопатий
EA201492279A1 (ru) Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
PH12017500747A1 (en) Heterocyclic compound
EA201790315A1 (ru) Модуляторы x-рецепторов печени
PL3544941T3 (pl) Całościowy sposób oczyszczania odpadów biologicznych
MX2017001493A (es) Eleccion de micro acidos ribonucleicos (arn) como diana para trastornos metabolicos.
EP3407858A4 (en) METHOD FOR TREATING THE APPEARANCE OF THINNING HAIR
MX2016008968A (es) Compuestos organicos.
MX2016012045A (es) Derivados de estradiol 6-sustituido para el tratamiento de la enfermedad de alzheimer.
NZ728612A (en) Treatment of androgen deprivation therapy associated symptoms
EA201650085A1 (ru) Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида
ZA202001588B (en) Method of treating alzheimer's disease